137 related articles for article (PubMed ID: 16985100)
21. Molecular cloning and functional analysis of cytochrome P450 1A2 from Japanese monkey liver: comparison with marmoset cytochrome P450 1A2.
Narimatsu S; Oda M; Hichiya H; Isobe T; Asaoka K; Hanioka N; Yamano S; Shinoda S; Yamamoto S
Chem Biol Interact; 2005 Feb; 152(1):1-12. PubMed ID: 15766918
[TBL] [Abstract][Full Text] [Related]
22. Metabolism of rofecoxib in vitro using human liver subcellular fractions.
Slaughter D; Takenaga N; Lu P; Assang C; Walsh DJ; Arison BH; Cui D; Halpin RA; Geer LA; Vyas KP; Baillie TA
Drug Metab Dispos; 2003 Nov; 31(11):1398-408. PubMed ID: 14570773
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of rat liver microsomal CYP1A2 and CYP2B1 activity by N-(2-heptyl)-N-methyl-propargylamine and by N-(2-heptyl)-propargylamine.
Dyck LE; Davis BA
Drug Metab Dispos; 2001 Aug; 29(8):1156-61. PubMed ID: 11454735
[TBL] [Abstract][Full Text] [Related]
24. Selective inhibitory effects of suberosin on CYP1A2 in human liver microsomes.
Paudel S; Jo H; Lee T; Lee S
Biopharm Drug Dispos; 2023 Oct; 44(5):365-371. PubMed ID: 37448189
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.
Kobayashi K; Nakajima M; Chiba K; Yamamoto T; Tani M; Ishizaki T; Kuroiwa Y
Br J Clin Pharmacol; 1998 Apr; 45(4):361-8. PubMed ID: 9578183
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibitory effects of mollugin on CYP1A2 in human liver microsomes.
Kim H; Choi HK; Jeong TC; Jahng Y; Kim DH; Lee SH; Lee S
Food Chem Toxicol; 2013 Jan; 51():33-7. PubMed ID: 23000442
[TBL] [Abstract][Full Text] [Related]
27. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine.
von Moltke LL; Greenblatt DJ; Duan SX; Schmider J; Kudchadker L; Fogelman SM; Harmatz JS; Shader RI
Psychopharmacology (Berl); 1996 Dec; 128(4):398-407. PubMed ID: 8986010
[TBL] [Abstract][Full Text] [Related]
28. The inhibitory effect of tannic acid on cytochrome P450 enzymes and NADPH-CYP reductase in rat and human liver microsomes.
Yao HT; Chang YW; Lan SJ; Yeh TK
Food Chem Toxicol; 2008 Feb; 46(2):645-53. PubMed ID: 17950511
[TBL] [Abstract][Full Text] [Related]
29. Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo.
Karjalainen MJ; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2008 May; 64(5):511-9. PubMed ID: 18197403
[TBL] [Abstract][Full Text] [Related]
30. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A
Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252
[TBL] [Abstract][Full Text] [Related]
31. Elucidation of the effects of the CYP1A2 deficiency polymorphism in the metabolism of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-d]pyrimidine-2-(1h)-one (YM-64227), a phosphodiesterase type 4 inhibitor, and its metabolites in dogs.
Tenmizu D; Noguchi K; Kamimura H
Drug Metab Dispos; 2006 Nov; 34(11):1811-6. PubMed ID: 16882764
[TBL] [Abstract][Full Text] [Related]
32. Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2.
Shet MS; McPhaul M; Fisher CW; Stallings NR; Estabrook RW
Drug Metab Dispos; 1997 Nov; 25(11):1298-303. PubMed ID: 9351907
[TBL] [Abstract][Full Text] [Related]
33. Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation?
Fairman DA; Collins C; Chapple S
Drug Metab Dispos; 2007 Dec; 35(12):2159-65. PubMed ID: 17823234
[TBL] [Abstract][Full Text] [Related]
34. Cyp1a2 protects against reactive oxygen production in mouse liver microsomes.
Shertzer HG; Clay CD; Genter MB; Schneider SN; Nebert DW; Dalton TP
Free Radic Biol Med; 2004 Mar; 36(5):605-17. PubMed ID: 14980704
[TBL] [Abstract][Full Text] [Related]
35. Differential inhibition of rat and human hepatic cytochrome P450 by Andrographis paniculata extract and andrographolide.
Pekthong D; Martin H; Abadie C; Bonet A; Heyd B; Mantion G; Richert L
J Ethnopharmacol; 2008 Feb; 115(3):432-40. PubMed ID: 18053665
[TBL] [Abstract][Full Text] [Related]
36. Role of CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction.
Peterson TC; Peterson MR; Wornell PA; Blanchard MG; Gonzalez FJ
Biochem Pharmacol; 2004 Jul; 68(2):395-402. PubMed ID: 15194011
[TBL] [Abstract][Full Text] [Related]
37. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P
Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550
[TBL] [Abstract][Full Text] [Related]
38. Binimetinib Is a Potent Reversible and Time-Dependent Inhibitor of Cytochrome P450 1A2.
Dong J; Li S; Liu G
Chem Res Toxicol; 2021 Apr; 34(4):1169-1174. PubMed ID: 33728909
[TBL] [Abstract][Full Text] [Related]
39. Identification and characterization of psoralen and isopsoralen as potent CYP1A2 reversible and time-dependent inhibitors in human and rat preclinical studies.
Zhuang XM; Zhong YH; Xiao WB; Li H; Lu C
Drug Metab Dispos; 2013 Nov; 41(11):1914-22. PubMed ID: 23975028
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of human liver cytochrome P-450 1A2 by the class IB antiarrhythmics mexiletine, lidocaine, and tocainide.
Wei X; Dai R; Zhai S; Thummel KE; Friedman FK; Vestal RE
J Pharmacol Exp Ther; 1999 May; 289(2):853-8. PubMed ID: 10215663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
